Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5825.

https://doi.org/10.1182/blood-2025-5825

Published: 2025

Journal Articles

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Yasmin Karimi, Chan Cheah, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim Linton, Tycel Phillips, Won Seog Kim, Pegah Jafarinasabian, Barbara D'Angelo Månsson, Milan Geybels, Christian Eskelund, Martin Hutchings, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2025-5513

Published: 2025

Journal Articles

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Chan Cheah, Tycel Phillips, Wojciech Jurczak, Tae Min Kim, Kim Linton, Julie Vose, Jieying Jiang, Mohammad Atiya, Christian Eskelund, Charles Kearns, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5511.

https://doi.org/10.1182/blood-2025-5511

Published: 2025

Journal Articles

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Daniel Morillo, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Raul Cordoba, Toshihiko Oki, Monica Wielgos-Bonvallet, Mina Khoshdeli, Yi Hao, Jennifer Marek, Malene Risum, David Belada

Blood (2025) 146 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2025-1955

Published: 2025

Journal Articles

EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress

Paolo Strati, Philip Thompson, David Andorsky, Stefano Luminari, Kim Linton, Poliana Patah, Jian Mei, Neha Joshi, Neha Dixit, Elena Favaro, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 5393.

https://doi.org/10.1182/blood-2025-5393

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 5370.

https://doi.org/10.1182/blood-2025-5370

Published: 2025

Journal Articles

Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up

Catherine Thieblemont, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Cheah, Jieying Jiang, Mohammad Atiya, Christian Eskelund, Derek Woods, Tycel Phillips

Blood (2025) 146 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2025-1960

Published: 2025

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Nirav Shah, Scott Huntington, David Lewis, Talha Munir, Graham Collins, Alvaro Alencar, Kim Linton, Zulfa Omer, Dima El-Sharkawi, Mary Gleeson, Pamela McKay, Jeanette Doorduijn, Jeffery Smith, Daniel Morillo, Pau Abrisqueta, Sarah Injac, Astrid Pulles

Blood (2025) 146 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2025-5359

Published: 2025

Journal Articles

Frontline treatment of follicular lymphoma: what will it take to change current practice?

Emmanuel Bachy, Kim Linton

Blood (2025) 146 (15): 1770–1781.

https://doi.org/10.1182/blood.2024026019

Published: 2025

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Tycel J. Phillips, Michael Roost Clausen, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Y Cheah, Jieying Jiang, Kubra Karagoz, Mohammad Atiya, Christian Eskelund, Han Si, Edith Szafer Glusman, Andrew J. Steele, Charles Kearns, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2024-199799

Published: 2024

Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Blood (2024) 144 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2024-203781

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Joshua Brody, Lorenzo Falchi, Umberto Vitolo, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Poliana Patah, Jennifer Marek, Christopher Morehouse, Andrew J. Steele, Yi Hao, Daniela Hoehn, Kim Linton

Blood (2024) 144 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2024-200369

Published: 2024

Journal Articles

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Kim Linton, John N. Allan, Andrew S Park, Anthony W Wang, Summer Tran, Alex Mutebi, Zhijie Ding, Quan Chen, Tycel J. Phillips

Blood (2024) 144 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2024-200989

Published: 2024

Journal Articles

Outcomes of Novel Agents Compared to Conventional Treatment in Relapsed and Refractory Diffuse Large B Cell Lymphoma after Second Line Chemoimmunotherapy at the Christie, a Single Centre Retrospective Study

Sonia Raj, Xin Wang, Kim Linton

Blood (2024) 144 (Supplement 1): 6489.

https://doi.org/10.1182/blood-2024-200200

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raul Cordoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Kimberly G. Archer, Ali Rana, David Belada

Blood (2024) 144 (Supplement 1): 581.

https://doi.org/10.1182/blood-2024-198023

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil

Blood (2024) 144 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2024-200957

Published: 2024

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Frontline treatment of follicular lymphoma: what will it take to change current practice?

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Outcomes of Novel Agents Compared to Conventional Treatment in Relapsed and Refractory Diffuse Large B Cell Lymphoma after Second Line Chemoimmunotherapy at the Christie, a Single Centre Retrospective Study

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only